IGF-1 LR3 and PEG-MGF Interaction: Monitor | Peptide Database

FDA-approved indication. Stanozolol increases plasma levels of C1-esterase inhibitor and C4 complement, reducing the frequency and severity of angioedema episodes characterized by localized swelling of the skin, mucous membranes, and internal organs. Previously used to stimulate erythropoiesis in patients with aplastic anemia and other bone marrow failure states. Largely replaced by erythropoietin-stimulating agents and other modern therapies, though it demonstrated efficacy in stimulating red blood cell production. Widely used during caloric deficit phases to preserve lean mass and enhance muscle hardness, vascularity, and definition. The absence of water retention produces a dry, striated appearance that is highly valued in competitive bodybuilding. Provides significant increases in maximal and explosive strength without substantial body weight gain. Historically popular in weight-class-restricted sports, track and field, and combat sports for this reason. Enhances speed and power output through improved neuromuscular efficiency, increased red blood cell count, and enhanced protein synthesis. The lack of water weight gain is advantageous for athletes where power-to-weight ratio is critical. Anti-catabolic properties help preserve lean tissue during aggressive caloric restriction. The potent SHBG suppression enhances free testosterone levels, further supporting muscle preservation.

Join others researching Dutasteride — share findings, ask questions, and learn from real experiences Dutasteride is a potent dual 5-alpha reductase inhibitor that blocks both Type I and Type II isoforms of the enzyme responsible for converting testosterone to dihydrotestosterone (DHT). FDA-approved at 0.5mg daily for benign prostatic hyperplasia (BPH) under the brand name Avodart, it is widely used off-label for the treatment of androgenetic alopecia (male pattern hair loss). By inhibiting both isoforms, dutasteride achieves approximately 90% suppression of serum DHT, compared to roughly 70% with finasteride, which blocks only the Type II isoform. This greater DHT suppression translates to potentially superior hair regrowth outcomes in head-to-head comparisons, though it also carries a somewhat higher risk of DHT-related side effects. Dutasteride has an exceptionally long half-life of approximately 5 weeks, meaning it takes several months to reach steady-state levels and equally long for effects to fully wash out after discontinuation. Dutasteride competitively inhibits both the Type I and Type II isoforms of the enzyme 5-alpha reductase. Type II is the predominant isoform in the prostate and hair follicles, while Type I is found primarily in the skin, sebaceous glands, and liver. By blocking both isoforms, dutasteride suppresses serum DHT levels by approximately 90% at the standard 0.5mg dose, compared to the roughly 70% suppression achieved by finasteride (which blocks only Type II). This near-complete DHT suppression more effectively reduces the androgenic stimulus driving follicular miniaturization in genetically susceptible individuals. The exceptionally long elimination half-life of approximately 5 weeks is due to extensive tissue binding and slow clearance. Serum testosterone may increase modestly (10-20%) as a compensatory response to the pronounced reduction in DHT, though this increase remains within the normal physiological range for most men.